FDA awards RMAT status to 4DMT diabetic macular oedema therapy

4D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for 4D-150.

Related Posts

Regeneron gene therapy improves hearing in child

Oct 28, 2023

FDA greenlights first over-the-counter birth control pill

Jul 13, 2023

Chinese NMPA approves AstraZeneca’s Calquence for leuka...

Sep 5, 2023